STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRAX
  4. [8-K] Praxis Precision Medicines, Inc. Reports Material Event

Praxis (NASDAQ: PRAX) vormatrigine focal seizure study misses main goal but shows signals

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Praxis Precision Medicines reported clinical trial results for vormatrigine in patients with focal onset seizures. In the Phase 2/3 POWER1 study in highly refractory patients, vormatrigine did not meet the primary success measure, which is a setback for this program. A key secondary measure, the 50% response rate, was met, and seizure reduction in the second half of the study at the higher 30 mg dose was more pronounced, suggesting some dose-related benefit. Vormatrigine was generally well tolerated, with adverse event-related discontinuations under 10%, and about 90% of patients from the vormatrigine arm moved into and remain in the open-label extension. The company is pausing enrollment in the POWER2 study while it reassesses the vormatrigine program and considers potential modifications.

Positive

  • Secondary efficacy signal and tolerability: The POWER1 study met its 50% response rate secondary measure, seizure reduction improved on the higher 30 mg dose in the latter half of the study, and adverse event-related discontinuations were under 10%, supporting a potentially workable safety and dosing profile.
  • Strong patient retention: Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open-label extension study, indicating sustained engagement and tolerability that may support further analysis or redesigned trials.

Negative

  • Primary endpoint failure in pivotal-stage study: The Phase 2/3 POWER1 trial in highly refractory focal onset seizure patients did not meet its primary success measure, which is a material setback for vormatrigine’s current development path and may reduce the asset’s near-term value.
  • Program pause for reassessment: Enrollment in the POWER2 study is being paused while Praxis reassesses the vormatrigine program and considers modifications, introducing uncertainty about timeline, strategy, and ultimate viability for this indication.

Insights

Missed primary endpoint is a material setback despite secondary and safety positives.

Praxis Precision Medicines disclosed that vormatrigine in the Phase 2/3 POWER1 study for focal onset seizures did not achieve its primary success measure in highly refractory patients. For a neurology asset, failure on the primary endpoint is a significant negative for the program’s current design.

The study did meet a key secondary endpoint, the 50% response rate, and showed more pronounced seizure reduction in the second half of the trial at the higher 30 mg dose. Vormatrigine was generally well tolerated, with under 10% adverse event-related discontinuations, and strong continuation into the open-label extension, with about 90% of vormatrigine-arm patients transitioning.

However, the company is pausing enrollment in the POWER2 study to reassess and consider modifications. Future disclosures in company filings may indicate whether the program can be redesigned around dose, patient selection, or endpoints, or whether resources shift to other assets.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Study phase Phase 2/3 POWER1 vormatrigine trial in focal onset seizures
Dose level 30 mg Higher dose used in second half of POWER1 study
Adverse event discontinuations <10% Patients discontinuing vormatrigine due to adverse events in POWER1
Open-label extension participation ≈90% of patients Vormatrigine-arm patients transitioning to and remaining in extension
Phase 2/3 medical
"results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients"
A phase 2/3 trial is a combined clinical study that first evaluates how well a treatment works and the best dose, then expands into a larger test to confirm those results and safety. For investors, it matters because moving into a phase 2/3 signals that an experimental therapy has shown initial promise and will be tested at scale, which can materially change the odds and timeline for regulatory approval and commercial potential.
focal onset seizures medical
"POWER1 study evaluating vormatrigine in patients with focal onset seizures"
Focal onset seizures are seizures that begin in a specific part of the brain and can cause localized symptoms such as brief changes in awareness, unusual sensations, or jerking in one limb; they can sometimes spread to affect the whole brain. Investors care because these seizures define patient groups, influence how drugs and devices are tested and approved, and shape market size, pricing and risk — like a localized outage that requires a targeted fix rather than a whole-system replacement.
open label extension study medical
"remain in the open label extension study"
forward-looking statements regulatory
"contains forward-looking statements within the meaning of the Private Securities"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
FALSE000168954800016895482026-06-012026-06-01

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2026
PRAXIS PRECISION MEDICINES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-39620
47-5195942
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

Praxis Precision Medicines, Inc.
99 High Street, 30th Floor
Boston, Massachusetts 02110
(Address of principal executive offices, including zip code)
(617) 300-8460
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trade
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share PRAX The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 


Item 8.01. Other Events.
On June 1, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures (“FOS”). The POWER1 study in highly refractory patients with FOS did not meet its primary success measure. The secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced. Vormatrigine was generally well-tolerated and adverse event-related discontinuations were less than 10%. Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open label extension study.
The Company is pausing enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the clinical development of vormatrigine. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, including, without limitation, uncertainties inherent in clinical trials and other risks as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report on Form 8-K. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.








SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PRAXIS PRECISION MEDICINES, INC.
Date: June 1, 2026By: /s/ Marcio Souza
 Marcio Souza
 Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Praxis Precision Medicines (PRAX) report about the POWER1 vormatrigine study?

Praxis Precision Medicines reported that the Phase 2/3 POWER1 study of vormatrigine in highly refractory focal onset seizures did not meet its primary success measure. However, a key secondary 50% response rate endpoint was achieved, and seizure reductions improved at the higher 30 mg dose later in the trial.

Did vormatrigine show any positive efficacy signals in PRAX’s POWER1 trial?

Yes. While the primary endpoint was not met, the POWER1 study achieved its secondary 50% response rate measure. Seizure reduction was more pronounced during the second half of the study at the higher 30 mg dose, suggesting a potentially dose-related efficacy signal that might inform future development plans.

How well tolerated was vormatrigine in PRAX’s POWER1 focal onset seizure study?

Vormatrigine was generally well tolerated in the POWER1 study. Adverse event-related discontinuations were reported at under 10%, indicating a relatively favorable tolerability profile. This safety outcome could be important if Praxis decides to modify and continue the program in future trials.

What proportion of PRAX POWER1 patients entered the open-label extension for vormatrigine?

Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open-label extension study. This high transition rate suggests continued patient and investigator engagement with treatment and allows additional data collection on longer-term use and safety.

What is Praxis Precision Medicines (PRAX) doing with the POWER2 study after POWER1 results?

Praxis is pausing enrollment in the POWER2 study following the POWER1 results. The company plans to reassess the vormatrigine program and determine potential modifications, which could include changes to trial design, dosing strategy, or other development plans depending on further analysis.

What risks did PRAX highlight regarding further vormatrigine development?

Praxis emphasized that statements about vormatrigine’s clinical development are forward-looking and subject to risks, including uncertainties inherent in clinical trials. The company referenced additional risks described in its Form 10-K for the year ended December 31, 2025 and other SEC filings as important context for investors.

Filing Exhibits & Attachments

3 documents

Other Documents